Corvus Pharmaceuticals CRVS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$44.17M-6.7% | -$15.28M+75.5% | -$15.08M+73.5% | -$45.14M-99.6% | -$41.4M-66.5% | ||
| $112K+33.3% | $105K+23.5% | $99K+6.5% | $92K-9.8% | $84K-28.2% | ||
| $6.73M+88.8% | $5.33M+77.5% | $4.57M+65.4% | $4.05M+57.4% | $3.57M+52.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $101K— | $1.92M— | -$301K— | ||
| $3.11M+1,657% | $2.76M+1,227% | $1.51M+538% | $709K+378% | -$200K+87.9% | ||
| -$344K-250% | -$338K-1,307% | $643K+134% | $434K+125% | $230K+119% | ||
| -$2.02M+49.2% | -$1.96M+38.8% | -$3.43M-41.1% | -$3.78M-45.0% | -$3.97M-19.7% | ||
| -$319K— | -$185K— | —— | —— | —— | ||
| $1.09M— | $223K— | $600K— | $497K— | —— | ||
| -$34.91M-22.4% | -$32.8M-29.0% | -$32.07M-44.9% | -$28.83M-35.7% | -$28.53M-36.0% | ||
| $229K— | $174K— | —— | —— | —— | ||
| $245.78M+236% | $91.75M+30.8% | $98.69M+61.3% | $86.38M+95.6% | $73.2M+89.7% | ||
| $89.12M+78.3% | $84.13M+97.3% | $74.08M+97.7% | $60.49M+44.4% | $50M+1.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$24.76M— | -$26.03M— | -$23.23M— | ||
| $189.81M+1,409% | $684K-95.8% | $4.77M— | $8.51M— | $12.58M— | ||
| $226.9M— | $36.43M— | $55.02M— | $54.71M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.07M-16.4% | $1.35M+17.9% | $1.33M+29.2% | $1.39M+86.2% | $1.28M+64.0% | ||
| -$2.02M+49.2% | -$1.96M+38.8% | -$3.43M-41.1% | -$3.78M-45.0% | -$3.97M-19.7% | ||
| $3.11M+1,657% | $2.76M+1,227% | $1.51M+538% | $709K+378% | -$200K+87.9% | ||
| -$319K— | -$185K— | —— | —— | —— | ||
| $1.09M— | $223K— | $600K— | $497K— | —— | ||
| —— | —— | —— | —— | $503K— | ||
| $89.12M+78.3% | $84.13M+97.3% | $74.08M+97.7% | $60.49M+44.4% | $50M+1.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $8.05M— | $8.25M— | ||
| -$319K— | -$185K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.77M-86.8% | $4.68M— | $7.59M— | $10.49M— | ||
| —— | —— | —— | —— | —— | ||
| -$35.14M— | -$32.97M— | —— | —— | —— | ||
| -$35.14M— | -$32.97M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corvus Pharmaceuticals generate?
- Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.
- What is Corvus Pharmaceuticals's free cash flow?
- After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.
- Where does Corvus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.